Know the news early: Treatment of resistance to ixazomib

Ixazomib is a proteasome inhibitor used to treat multiple myeloma. Although ixazomib shows good therapeutic effects in most patients, some patients may develop drug resistance. The following strategies can be adopted to deal with the problem of ixazomib resistance:

1. Drug combination therapy: Use ixazomib in combination with other drugs with different mechanisms of action, such as rituximab, dexamethasone, etc. This combination therapy can increase the resistance to tumor cells and reduce the incidence of drug resistance.

2. Adjust the dose and dosing schedule: Depending on the patient’s specific conditions, the dose or dosing schedule of ixazomib may need to be adjusted. This can enhance the therapeutic effect of the drug by reducing dosing intervals, increasing dosage, etc.

4. Find new treatments: Continuous research and development can help us find new treatments to overcome the problem of ixazomib resistance. This may include developing new drugs, using immunotherapy or other targeted treatments.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.